Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
Animals
Autophagy
Disease Models, Animal
Fatty Liver
/ genetics
Female
GTP Phosphohydrolases
/ genetics
GTP-Binding Proteins
/ biosynthesis
Gene Expression Regulation
Hep G2 Cells
Hepatocytes
/ metabolism
Humans
Lipase
/ biosynthesis
Lipid Metabolism
/ genetics
Liver
/ metabolism
Male
Mice
Mice, Inbred C57BL
Microtubule-Associated Proteins
/ biosynthesis
Phenotype
RNA
/ genetics
Fatty liver
Immunity-related GTPases
NAFLD
Positional cloning
miRNA
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
25
10
2019
revised:
08
04
2020
accepted:
16
04
2020
pubmed:
8
5
2020
medline:
16
11
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Currently, only a few genetic variants explain the heritability of fatty liver disease. Quantitative trait loci (QTL) analysis of mouse strains has identified the susceptibility locus Ltg/NZO (liver triglycerides from New Zealand obese [NZO] alleles) on chromosome 18 as associating with increased hepatic triglycerides. Herein, we aimed to identify genomic variants responsible for this association. Recombinant congenic mice carrying 5.3 Mbp of Ltg/NZO were fed a high-fat diet and characterized for liver fat. Bioinformatic analysis, mRNA profiles and electrophoretic mobility shift assays were performed to identify genes responsible for the Ltg/NZO phenotype. Candidate genes were manipulated in vivo by injecting specific microRNAs into C57BL/6 mice. Pulldown coupled with mass spectrometry-based proteomics and immunoprecipitation were performed to identify interaction partners of IFGGA2. Through positional cloning, we identified 2 immunity-related GTPases (Ifgga2, Ifgga4) that prevent hepatic lipid storage. Expression of both murine genes and the human orthologue IRGM was significantly lower in fatty livers. Accordingly, liver-specific suppression of either Ifgga2 or Ifgga4 led to a 3-4-fold greater increase in hepatic fat content. In the liver of low-fat diet-fed mice, IFGGA2 localized to endosomes/lysosomes, while on a high-fat diet it associated with lipid droplets. Pulldown experiments and proteomics identified the lipase ATGL as a binding partner of IFGGA2 which was confirmed by co-immunoprecipitation. Both proteins partially co-localized with the autophagic marker LC3B. Ifgga2 suppression in hepatocytes reduced the amount of LC3B-II, whereas overexpression of Ifgga2 increased the association of LC3B with lipid droplets and decreased triglyceride storage. IFGGA2 interacts with ATGL and protects against hepatic steatosis, most likely by enhancing the binding of LC3B to lipid droplets. The genetic basis of non-alcoholic fatty liver disease remains incompletely defined. Herein, we identified members of the immunity-related GTPase family in mice and humans that act as regulators of hepatic fat accumulation, with links to autophagy. Overexpression of the gene Ifgga2 was shown to reduce hepatic lipid storage and could be a therapeutic target for the treatment of fatty liver disease.
Sections du résumé
BACKGROUND & AIMS
Currently, only a few genetic variants explain the heritability of fatty liver disease. Quantitative trait loci (QTL) analysis of mouse strains has identified the susceptibility locus Ltg/NZO (liver triglycerides from New Zealand obese [NZO] alleles) on chromosome 18 as associating with increased hepatic triglycerides. Herein, we aimed to identify genomic variants responsible for this association.
METHODS
Recombinant congenic mice carrying 5.3 Mbp of Ltg/NZO were fed a high-fat diet and characterized for liver fat. Bioinformatic analysis, mRNA profiles and electrophoretic mobility shift assays were performed to identify genes responsible for the Ltg/NZO phenotype. Candidate genes were manipulated in vivo by injecting specific microRNAs into C57BL/6 mice. Pulldown coupled with mass spectrometry-based proteomics and immunoprecipitation were performed to identify interaction partners of IFGGA2.
RESULTS
Through positional cloning, we identified 2 immunity-related GTPases (Ifgga2, Ifgga4) that prevent hepatic lipid storage. Expression of both murine genes and the human orthologue IRGM was significantly lower in fatty livers. Accordingly, liver-specific suppression of either Ifgga2 or Ifgga4 led to a 3-4-fold greater increase in hepatic fat content. In the liver of low-fat diet-fed mice, IFGGA2 localized to endosomes/lysosomes, while on a high-fat diet it associated with lipid droplets. Pulldown experiments and proteomics identified the lipase ATGL as a binding partner of IFGGA2 which was confirmed by co-immunoprecipitation. Both proteins partially co-localized with the autophagic marker LC3B. Ifgga2 suppression in hepatocytes reduced the amount of LC3B-II, whereas overexpression of Ifgga2 increased the association of LC3B with lipid droplets and decreased triglyceride storage.
CONCLUSION
IFGGA2 interacts with ATGL and protects against hepatic steatosis, most likely by enhancing the binding of LC3B to lipid droplets.
LAY SUMMARY
The genetic basis of non-alcoholic fatty liver disease remains incompletely defined. Herein, we identified members of the immunity-related GTPase family in mice and humans that act as regulators of hepatic fat accumulation, with links to autophagy. Overexpression of the gene Ifgga2 was shown to reduce hepatic lipid storage and could be a therapeutic target for the treatment of fatty liver disease.
Identifiants
pubmed: 32376415
pii: S0168-8278(20)30275-0
doi: 10.1016/j.jhep.2020.04.031
pmc: PMC7957830
mid: NIHMS1676339
pii:
doi:
Substances chimiques
Ifi1 protein, mouse
0
Map1lc3b protein, mouse
0
Microtubule-Associated Proteins
0
RNA
63231-63-0
Lipase
EC 3.1.1.3
PNPLA2 protein, mouse
EC 3.1.1.3
GTP Phosphohydrolases
EC 3.6.1.-
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
771-782Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM070683
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 European Association for the Study of the Liver. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Cell Metab. 2016 Jan 12;23(1):113-27
pubmed: 26698918
Hum Mol Genet. 2012 Sep 1;21(17):3845-57
pubmed: 22692684
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
J Hepatol. 2016 Dec;65(6):1209-1216
pubmed: 27417217
Nucleic Acids Res. 2014 Jan;42(Database issue):D142-7
pubmed: 24194598
World J Gastroenterol. 2015 Oct 21;21(39):11088-111
pubmed: 26494964
Trends Immunol. 2004 Nov;25(11):601-9
pubmed: 15489189
J Nutr Biochem. 2019 Jan;63:109-116
pubmed: 30359860
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Semin Liver Dis. 2004 Nov;24(4):349-62
pubmed: 15605303
J Cell Biol. 2018 Mar 5;217(3):997-1013
pubmed: 29420192
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Genet. 2015 May 19;6:188
pubmed: 26042150
Hepatology. 2013 Sep;58(3):966-75
pubmed: 23564467
Dev Cell. 2018 Oct 22;47(2):205-221.e7
pubmed: 30352176
Metabolism. 2016 Jun;65(6):805-15
pubmed: 27173459
J Lipid Res. 2018 Mar;59(3):531-541
pubmed: 29326160
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Oct;1862(10 Pt B):1131-1145
pubmed: 28642195
Science. 2006 Sep 8;313(5792):1438-41
pubmed: 16888103
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
J Lipid Res. 2012 Aug;53(8):1493-501
pubmed: 22628617
Cancer Res. 2017 Nov 1;77(21):5963-5976
pubmed: 28883000
J Hepatol. 2017 Sep;67(3):653-655
pubmed: 28483681
Cell Rep. 2017 Apr 4;19(1):1-9
pubmed: 28380348
J Lipid Res. 2009 Oct;50(10):2111-6
pubmed: 19738004
Nature. 2011 Sep 14;477(7364):326-9
pubmed: 21921916
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Hum Mol Genet. 2018 Sep 1;27(17):3099-3112
pubmed: 29893858
Nat Genet. 2014 Apr;46(4):352-6
pubmed: 24531328
Genetics. 2018 Dec;210(4):1527-1542
pubmed: 30341086
Mol Metab. 2018 Feb;8:167-179
pubmed: 29203237
Nat Rev Endocrinol. 2018 Mar;14(3):140-162
pubmed: 29348476
Bioinformatics. 2016 May 15;32(10):1555-6
pubmed: 26794315
Cell Metab. 2010 Jun 9;11(6):467-78
pubmed: 20519119
Mol Metab. 2017 Oct;6(10):1254-1263
pubmed: 29031724
Nat Genet. 2008 Dec;40(12):1461-5
pubmed: 18820647
Physiol Genomics. 2008 Jun 12;34(1):42-53
pubmed: 18397992
N Engl J Med. 2011 Dec 22;365(25):2357-65
pubmed: 22149959
Nature. 2009 Oct 8;461(7265):747-53
pubmed: 19812666
PLoS One. 2012;7(5):e37026
pubmed: 22615880
Hepat Med. 2017 Nov 06;9:55-66
pubmed: 29158695
Nature. 2011 Sep 14;477(7364):289-94
pubmed: 21921910
Genome Biol. 2005;6(11):R92
pubmed: 16277747